A phase I/IIa study of the safety, immunogenicity and parasite growth inhibitory activity of AMA1-C1 Alhydrogel + CPG 7909, an asexual blood stage vaccine for Plasmodium falciparum Malaria.

Trial Profile

A phase I/IIa study of the safety, immunogenicity and parasite growth inhibitory activity of AMA1-C1 Alhydrogel + CPG 7909, an asexual blood stage vaccine for Plasmodium falciparum Malaria.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Agatolimod (Primary) ; Malaria vaccine (Primary) ; Aluminium hydroxide
  • Indications Falciparum malaria
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 15 Oct 2011 United Kingdom Clinical Research Network reports accrual to date changed from 447% to 100%.
    • 07 Apr 2011 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network.
    • 07 Apr 2011 Planned end date changed from 1 Apr 2010 to 1 Mar 2011 as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top